MXC: $0.073
What We Grow

MGC Pharmaceutical’s Botanic Division works with numerous agricultural sites to meet growing demand worldwide, together with exploration into breeding and genetics with prominent establishments and academia. Dedicated to the growth of new genetics, focusing on certain medical indications, this division is where all GMP raw material for our clinical studies is created for patient treatment all over the globe.

Research and Development
  • Improving and stabilising MGC Pharma’s genetic bank in order to match treatments and indications, and to ensure our ability to seamlessly create products of identical high quality worldwide, to be fed into our pipelines.
  • University of Ljubljana botanic research project set to commence in order to develop new genetic strains.
  • Collaboration with Academy of Science, Czech Republic, on multiple strain grows.
Business Development

Botanic Division: We will continue to harvest the product in Slovenia and Czech Republic, and utilize the raw material at our production facility, as well as provide the product globally.

Projects
  • Project with Panax at the Academy of Science in Prague, progressing on schedule
  • Successful harvests at Slovenian growing site completed, with next harvest yielding product viable for pharmaceutical API and cosmetics.
Partners
  • Commencing global collaborations with various revenue models, including licensing proprietary MGC Pharma IP to collaborative partners in various geographies.